Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies.
We report two cases of late recurrence of eruptive locoregional metastatic melanoma occurring 6 and 9 years after definitive surgical treatment. Each case (stage IB and IA) occurred after initiation of the subcutaneous anti-tumor necrosis factor medications etanercept and adalimumab, respectively. We discuss the association of immune suppression and melanoma. These cases illustrate a previously unrecognized and potentially causal relationship between tumor necrosis factor-alpha inhibition and reactivation of latent melanoma.
Fulchiero
Gregory J
GJ
Department of Dermatology, Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, Pennsylvania 17033, USA.
Salvaggio
Heather
H
Drabick
Joseph J
JJ
Staveley-O'Carroll
Kevin
K
Billingsley
Elizabeth M
EM
Marks
James G
JG
Helm
Klaus F
KF
D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D007279:Injections, Subcutaneous; D008545:Melanoma / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000473:pathology / Q000556:secondary; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000139:chemically induced*; D049268:Positron-Emission Tomography; D011565:Psoriasis / Q000188:drug therapy; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000473:pathology / Q000556:secondary; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab; D000068800:Etanercept